[go: up one dir, main page]

AU2004222783A1 - Treatment of premature ejaculation - Google Patents

Treatment of premature ejaculation Download PDF

Info

Publication number
AU2004222783A1
AU2004222783A1 AU2004222783A AU2004222783A AU2004222783A1 AU 2004222783 A1 AU2004222783 A1 AU 2004222783A1 AU 2004222783 A AU2004222783 A AU 2004222783A AU 2004222783 A AU2004222783 A AU 2004222783A AU 2004222783 A1 AU2004222783 A1 AU 2004222783A1
Authority
AU
Australia
Prior art keywords
administration
antidepressant
lungs
male
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004222783A
Inventor
Jakov Vaisman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PE PATENT HOLDCO Pty Ltd
Original Assignee
PE PATENT HOLDCO Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PE PATENT HOLDCO Pty Ltd filed Critical PE PATENT HOLDCO Pty Ltd
Priority to AU2004222783A priority Critical patent/AU2004222783A1/en
Publication of AU2004222783A1 publication Critical patent/AU2004222783A1/en
Priority to AU2005100183A priority patent/AU2005100183B4/en
Assigned to PE PATENT HOLDCO PTY LTD reassignment PE PATENT HOLDCO PTY LTD Request for Assignment Assignors: VAISMAN, JAKOV
Assigned to PE PATENT HOLDCO PTY LTD reassignment PE PATENT HOLDCO PTY LTD Alteration of Name(s) of Applicant(s) under S113 Assignors: WORLDWIDE PE PATENT HOLDCO PTY LTD
Priority to AU2010219328A priority patent/AU2010219328A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

-1- TITLE: TREATMENT OF PREMATURE EJACULATION Field of the Invention The invention relates to methods and compositions for the treatment of male sexual dysfunction, and particularly to the treatment of premature ejaculation.
Background Art Mechanical devices have been previously employed in attempts to prevent premature ejaculation. Such devices operate by reducing the stimulation of the penis, but are often awkward and uncomfortable and may not be particularly effective in desensitising the most sensitive part of the penis which is the glans.
Antidepressants have been administered orally, in tablet form, to treat premature ejaculation, although there are significant side effects with this approach. In particular, antidepressants can lead to nausea, vomiting and diziness. Furthermore, their effects are very sensitive to the amount and timing of food and alcohol ingested, as well as the amount of fat on the patient, so their effects can be unpredictable.
Premature ejaculation has been treated in the past by the topical application of compositions containing local anaesthetics, such as lidocaine, to the skin of the penis to reduce sensitivity.
One limitation of such a method of treatment is that the composition must be substantially removed from the skin prior to intercourse to avoid transferring the anaesthetic to a female partner, thereby reducing reduced vaginal sensitivity Overapplication of the topical anaesthetic composition is also possible, leading to substantially diminished enjoyment of intercourse by the male.
-2- Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.
It is an object of the present invention to overcome or ameliorate at least one of the abovementioned disadvantages of using conventional anaesthetics.
Description of the Invention According to a first aspect, the invention provides a method of treating premature ejaculation in a male comprising administering to the male an antidepressant via a route selected from the group consisting of i) mucosal administration, ii) administration to the lungs iii) local administration to the male genitalia, and iv) a combination of two or more of mucosal administration, administration to the lungs and local administration to the male genitalia.
Preferably, the mucosal administration is nasal administration although it may also be via other mucosal routes such as buccal administration or rectal administration.
Preferably, administration to the lungs is by way of inhalation.
Preferably, the local administration is directly to the penis.
Specifically, the antidepressant or a combination ofantidepressants is administered by one of the abovementioned routes alone or by a combination of mucosal (preferably nasal) and topical (preferably to the penis), or by a combination of mucosal (preferably nasal) and lung (preferably by inhalation), or by a combination of topical (preferably to the penis) and lung (preferably by inhalation), or even by a combination of all three, ie a combination of topical (preferably to the penis), mucosal (preferably nasal) and lung (preferably by inhalation) administration.
-3- The most preferred single modes of administration are nasal, to the lungs, and .buccal. The most preferred combination modes of administration are combinations of nasal and to the penis, lungs and to the penis, and buccal and to the penis.
For example, the treatment of the present invention maybe administered by way of a nasal spray, aninhaler or a troche, either alone or in combination with a suitable formulation applied to the penis. In combination therapies, the same or different antidepressants may be administered via different routes.
Without wishing to be bound by theory, it is believed the routes of the present invention allow the drugs to bypass the first metabolism of the liver, and cross the blood/brain barrier to act straight away on the brain. This mode of action may serve to explain the small doses used to achieve success, the rapid onset of action and the consistency in dose/response patterns.
The combination of topical (to the penis) and the mucosal routes above appear to result in a synergistic enhancement of the effect in preventing premature ejaculation.
According to a second aspect, the invention provides a method of treating premature ejaculation in a male comprising the step of administering to the male an antidepressant, wherein said antidepressant is administered via a route selected from the group consisting of i) nasal administration, ii) administration to the lungs, iii) buccal administration, iv) administration to the penis and v) a combination of two or more of nasal administration, administration to the lungs, buccal administration and local administration to the penis.
Surprisingly, the present inventor has found that antidepressants administered by these routes result in a sufficient degree of anaesthesia to the penis to overcome premature ejaculation.
-4- The term antidepressant as used herein refers to any substance used in the treatment of clinical depression. All antidepressants are believed to be suitable for use in the present invention.
In one preferred embodiment, the antidepressant is a selective serotonin reuptake inhibitor (known as an SSRI).
In alternative preferred embodiments the antidepressant is a bicyclic, tricyclic or tetracyclic antidepressant.
In yet another alternative preferred embodiment, the antidepressant is a monoamine oxidase inhibitor.
In further alternative preferred embodiments, the antidepressant may be selected from one of the following classes: Serotonin Norepinephrine Reuptake Inhibitors, Norepinephrine Dopamine Reuptake Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, Norepinephrine Antagonist/Serotonin Antagonists, Monoamine Oxidases (MAO) Inhibitors, synthetically derived phenylpiperazine antidepressants, antagonists of central L2-a2 auto and heteroadrenoceptors.
As mentioned, the inventor has found that an antidepressant agent, that is an agent that is more typically used for the treatment of clinical depression, is capable of delaying ejaculation when administered by nasal/lung/buccal or a combination of these, or in combination with administration to the penis, while minimising side effects typical of such antidepressants such as vomiting, nausea and dizziness.
Further, the agent can be administered at a fraction of the dose than is usually used to treat depression, with rapid onset of action and with a high degree of predictability.
.Importantly, for the treatment of premature ejaculation, the inventor has found that when topically applied to at-least a portion of the skin of the male genitalia, for example, when applied to the penis, an antidepressant agent will induce a sufficient degree of anaesthesia to provide an improvement to the condition of premature ejaculation..
Even more surprisingly, it has been found that administering antidepressants mucosally, preferably nasally, or by administrationto the lungs, delays ejaculation during intercourse.
A combination ofmucosal, preferably nasal, and local administration has been found to be extremely useful in preventing premature ejaculation and prolonging sexual intercourse.
Alternatively, a combination of administration to the lungs, and local administration has been found to be extremely useful in preventing premature ejaculation and prolonging sexual intercourse.
A further combination of routes of administration, namely a combination of mucosal, preferably nasal, and administration to the lungs has also been found to be valuable in preventing premature ejaculation and prolonging sexual intercourse.
One or more antidepressants may be used in combination, and they may be used alone or with one or more carriers for facilitating the application of the antidepressant agent to the skin or too the mucosa.
if a combination of two or more routes selected from mucosal administration, administration to the lungs and local administration is used, then the same antidepressant or antidepressant combination may be administered by the two or more different routes, or different antidepressants or combinations of antidepressants may be administered by the two or more different routes.
According to a third aspect, the invention provides a composition for the treatment of premature ejaculation, said composition comprising an antidepressant formulated for -6mucosal administration. More preferably, the antidepressant is formulated for nasal administration.
According to a fourth aspect, the invention provides a composition for the treatment of premature ejaculation, said composition comprising an antidepressant formulated for administration to the lungs. Most preferably, administration to the lungs is by inhalation.
According to a fifth aspect, the invention provides a composition including an antidepressant formulated for local administration to the male genitalia.
According to a sixth aspect, the invention provides a kit, said kit comprising an antidepressant formulated for nasal administration and an antidepressant formulated for topical application. Preferably, the antidepressants are selected such that a synergistic interaction occurs when there is a combination of nasal and local administration.
According to a seventh aspect, the invention provides a kit, said kit comprising an antidepressant formulated for administration to the lungs and an antidepressant formulated for topical application. Preferably, the antidepressants are selected such that a synergistic interaction occurs when there is a combination of lung and local administration.
According to a eighth aspect, the invention provides a kit, said kit comprising an antidepressant formulated for nasal administration and an antidepressant formulated for application to the lungs. Preferably, the antidepressants are selected such that a synergistic interaction occurs when there is a combination of nasal and lung administration.
According to a ninth aspect, the invention provides a kit, said kit comprising an antidepressant formulated for nasal administration, an antidepressant formulated for -7application to the lungs and an antidepressant formulated for topical administration..
Preferably, the antidepressants are selected such that a synergistic interaction.
According to a tenth aspect the invention provides a method of prolonging sexual intercourse involving a male, said method including the step of administering to said male prior to intercourse an amount of an antidepressant effective to delay ejaculation; and wherein said antidepressant is administered via a route selected from the group consisting of: mucosal administration, administration to the lungs, topical administration to the male genitalia, and a combination of two or more of mucosal administration, administration to the lungs or topical administration to the male genitalia.
According to an eleventh aspect the invention provides a method of prolonging sexual intercourse involving a male and a female, said method including the step of administering to said male prior to intercourse an amount of an antidepressant effective to delay ejaculation without anaesthetising the female genitalia; and wherein said antidepressant is administered via a route selected from the group consisting of: mucosal administration, administration to the lungs, topical administration to the male genitalia, and a combination of two or more of mucosal administration, administration to the lungs or topical administration to the male genitalia, Antidepressants As mentioned, any antidepressant is suitable for use in the present invention.
The antidepressants may be selected from: Selective Serotonin Reuptake Inhibitors (SSRI) Serotonin Norepinephrine Reuptake Inhibitors, (including bicyclic, tricyclic and tetracyclic antidepressants) Norepinephrine Dopamine Reuptake Inhibitors Serotonin Antagonist and Reuptake Inhibitors -8- Norepinephrine Antagonist/Serotonin Antagonists Monoamine Oxidases (MAO) Inhibitors Synthetically derived phenylpiperazine antidepressants antagonists of central L2-a2 auto and heteroadrenoceptors Some specific non-limiting examples of antidepressants include, but are not limited to paroxetine, fluoxoetine and sertraline. Paroxetine may be formulated as a hydrochloride (such as Aropax) or in the form of other salts or in combination with other bases such as mesylates. Other suitable antidepressants for use in the present invention include citalopram hydrobromide (Cipramil), fluoxetine (Prozac), fluvoxamine (Luvox), sertraline (Zoloft), nortriptyline hydrochloride (Allegron), clomipramine hydrochloride (Anafranil), dothiepin hydrochloride (Prothiaden), Imipramine hydrochloride (Tofranil), mianserin hydrochloride (Tolvon), amitriptyline hydrochloride (Tryptanol), phenelzine sulphate (Nardil), tranylcypromine sulphate (such as Pamate), isocarboxazid (Marplan), moclobemide (Aurorix), serotonin and/or adrenalin update inhibitors such as venlafaxine (Efexor), nefazodone hydrochloride (Serzone), trazodone (Desyrel), bupropion (Zyban), mirtazapine (Remeron), doxepin hydrochloride (Sinequan) and trimipramine (Surmontil).
Preferably, the antidepressant is administered in an amount of between 0.1 and 1000mg per dose, depending upon the nature of active ingredient used and the severity of the patients problems, as well as other factors such as patient size. More preferably, the dosage will be between 1 and 100mg antidepressant, even more preferably between and 25 mg antidepressant. The exact dosage will be readily determined by a trained clinician.
Topical Formulations
I
-9- For topically administered antidepressants, administration is typically by way of application either to the skin of the region of the male genitalia as a composition that may also include a carrier for facilitating the application of the antidepressant agent to the skin.
Compositions may be applied to the male genitalia in the form of a gel, although they may also be formulated as a lotion or a powder. It will be understood by those skilled in the art that the particular form of the composition is not important, provided that by contacting the composition with the skin in the male genital region, the antidepressant agent is permitted to induce anaesthesia that that region.
The composition may be applied to any part of the male genitalia, such as the penis only, or also to the scrotum or surrounding regions such as the perineum. Most usually, a topical composition comprising an antidepressant is applied directly to the penis.
The topical composition is typically applied by massaging into the skin for about one minute, preferably about 30 to 60 minutes prior to intercourse.
Preferably, the concentration of the antidepressant in a composition is between about 1 to 10% by weight, preferably about 3 to 6% by weight of the topical composition.
Preferably, the antidepressant in the topical formulation is present in an amount of between 0.1 and 1 000mg per dose, depending upon the active ingredieint used. More preferably, the dosage will be between 1 and 100mg antidepressant, even more preferably between 5 and 25 mg antidepressant.
It will be understood by those skilled in the art that more than one type of agent described above could be used in the composition of the invention, provided that the composition is capable of introducing anaesthesia ata region of male genitalia either to which the composition is applied, or to the appropriate regions by means ofmucosal administration.
The composition may be provided in the form of a gel or lotion, or alternatively, it may be provided as a powder which in use can be hydrated to form a gel or lotion suitable for application to a region of male genitalia.
Most typically, the composition is applied to the skin of the male genitalia as a gel.
A typical gel for.facilitating application of the antidepressant is a hydrogel such as hydroxypropylmethylcellulose (Methocell EM4), or an acrylic acid polymer such as Carbopol 943P. The polymer in the composition is present in the range of about 0.1 to about 5 wt%. The carrier is typically water soluble, non-irritating and does not sensitise the skin. It is desirable if the carrier imparts a semi soft creamlike consistency to the composition.
The topical compositions may further comprise an enhancer agent for enhancing the absorption of the antidepressant agent through the skin. Examples of enhancer agent include cyclodextrins such as and y-cyclodextrin and 2-methylcyclodextrin.
Hydroxypropyl-p-cyclodextrin HPBCD is particularly advantageous as compositions comprising HPBCD are suitable for use with diabetic men. HPBCD is a cyclic polymer having a ring shaped molecular structure including an inner cavity. It is understood that an inclusion compound is formed with HPBCD which makes the antidepressant more readily absorbed by the skin. The weight percent of the HPBCD in the composition is preferably in the range of about 1 to 10 HPBCD is a commercially available compound derived from P-cyclodextrin a condensation with propylene oxide to provide the corresponding hydroxypropyl derivative having a degree of substitution of up to about 15 or higher. A-degree of substitution of about 5 to about 7 is preferred for compositions of the present invention.
-11- The antidepressant agent and the HPBCD are typically present in the composition in a molar ratio of about 1:0.8 to 1:1.4 respectively. Preferably, the antidepressant agent and the HPBCD are present in a ratio of about 1:1.
The pHs of the compositions in the present invention are preferably in the range of about 2 to about 8, and more preferably, around 7.4. The pH can be adjusted by any physiologically suitable agent such as amoniumhydroxide or sodium hydroxide.
Other components of the composition may include water, monohydric and polyhydric alcohols such as ethanol, polyethylene glycol, propylene glycol and DMSO.
The amount of water in the composition is typically in the range of about 20 to about 60%, and alcohols typically about 80% to about 40%. The ethanol and the propylene glycol are preferably present in a relative weight ratio of about 3:1 to about 0:1.
Preferably, the composition need not be removed after application.
Mucosal Formulations For mucosally administered antidepressants, administration is via application to the mucosa of said male as a composition that may include a carrier for facilitating the application of the antidepressant agent to the mucosa.
Similarly, it will be understood that the compositions for mucosal administration may be in many forms. Most typically, the invention is formulated as a spray for nasal administration, although it may be formulated for buccal administration in the form of a troche or in the form of a suppository for rectal administration. Those skilled in the art will appreciate that the important consideration is to select the antidepressant, the dosage and the dosage form in combination to provide a sufficient quantity of antidepressant is present to induce a degree of anaesthesia in the male genitalia to prevent premature ejaculation.
-12- Nasal formulations include gels, suspension, liposomal dispersions, emulsions or microemulsions and may be any combination of aqueous and non-aqueous components.
Alternatively, the nasal formulations may be in powdered form, such as microspheres, liposomes. coated microspheres (for example, such as those with a cellulose or polysaccharide coating).
The nasal formulations of the present invention may include conventional additives and excipients, such as buffers, thickening agents, soothing agents, sweeteners and membrane conditioners or transport agents, antioxidants, preservatives, penetrating agents and other carriers which will be known by those skilled in the art. It is preferably dispensed via a.metered spray vessel. Administering the dose in a metered fashion enables a use of a defined quantity of the active ingredient involved.
Nasal formulations may typically include water, polyethylene glycols (various pharmaceutically acceptable PEG's,) glycerine, DMSO, ascorbic acid or ascorbate salts or bisulfites.
Preferably, the antidepressant in the nasal formulation is present in an amount of between 0.1 and 1000mg per dose, depending upon the active ingredient used. More preferably, the dosage will be between 1 and 100mg antidepressant, even more preferably between 5 and 25 mg antidepressant.
Preferably, the dosage is taken nasally just prior to intercourse, between 10 and minutes prior to intercourse, most preferably around 20 minutes prior to intercourse.
The nasal composition may be administered by means of one or two metered doses shortly before intercourse, or by way of a troche or suppository which are administered slightly further ahead of time.
-13- A typical nasal spray of the present invention contains antidepressant (name) such that a single dose typically delivers from 2 to 50 mg antidepressant (name). The volume of one actuation of a metered dose is generally 20 to 500 microlitres.
antidepressant (name) 100mg Antioxidant 1% Preservative Dimethyl sulfoxide 0.02% Purified Water to 100.
Formulation for application to the lungs Any conventional formulation for administration to the lungs may be used.
Preferably, this is via inhalation. A propellant is preferably also included in such formulations.
The drug may be delivered in the form of, for example a dry powder, a micronized drug suspended in a liquefied propellant, or a drug dissolved, either alone or by way of a cosolvent, in a liquefied propellant.
Preferably, the particle size of the dry material is less than 10microns, and preferably less than about 5 microns Aerosols propellants include any agents suitable for medical use provided they are compatible with the active. They may be, for example, CFC (chlorofluorocarbon) or HFA (hydrofluoroalkane) propellants.
All types of nebuliser may be used pressure, powder, metered powder or ultrasonic.
-14- Where the active antidepressant is dissolved, a cosolvent may be added. A suitable cosolvent is, for example, ethanol.
Other ingredients, may be added to the formulations. These may include, for instance, surface active agents (surfactants). Any suitable Surface active agent may be used. These may include, for example, oleic acid, sorbitan trioleate and lecithin.
Preferably, the antidepressant is administered in an amount of between 0.1 and 1000mg per metered dose. More preferably, the dosage will be between 1 and 100mg antidepressant, even more preferably between 5 and 25 mg antidepressant.
Results A range of commonly available antidepressants were prepared and administered according to the present invention as described above.
All three routes of administration, oral, nasal and a combination of topical and nasal were found to produce a reduction in premature ejaculation as a whole. Those subjects taking the antidepressants by both the nasal and the topically administered formulations noted particularly good results.
For those patients taking the antidepressants by both routes, it may be advantageous if the antidepressants were selected from different groups, eg if one was an SSRI and the other was a MAO inhibitor, for example.
Antidepressants were administered to a large number of subjects in accordance with the method of the present invention. The study involved in excess of 200 patients in each treatment group. All subjects reported experiencing premature ejaculation prior to commencing the study. All medicaments were self administered. Topical administration was to the skin of the glans. Paroxetine, Fluoxetine and Sertraline were administered randomly via a mixture of routes.
Assessment was made by asking patients whether they were satisfied with the result. Almost all subjects reported an improvement in time to ejaculation. A combination of nasal and topical seemed to be most satisfactory, in providing the best result to the largest number of subjects.
While the invention is described with reference to specific embodiments, it will be understood by those skilled in the art that that variations and modifications may be made without departing from the inventive concept disclosed herein.

Claims (48)

1. A method of treating premature ejaculation in a male comprising administering to the male an antidepressant via a route selected from the group consisting of: i) mucosal administration; ii) administration to the lungs iii) local administration to at least a part of the male genitalia and iv) a combination of two or more of mucosal administration, administration to the lungs and local administration to at least a part of the male genitalia.
2. A method according to claim 1 wherein the antidepressant is administered prior to sexual activity
3. A method according to claim 1 or claim 2 wherein the antidepressant is administered during sexual activity
4. The method according to claim 1 wherein the mucosal administration is by nasal administration, buccal administration, rectal administration or combinations thereof. The method according to claim 1 wherein administration to the lungs is by way of inhalation.
6. The method according to claim 1 wherein local administration is directly to the penis. -17-
7. A method according to any one of claims 1 to 3 wherein the antidepressant is administered by a combination ofmucosal administration and local administration.
8. A method according to any one of claims 1 to 3 wherein the antidepressant is administered by a combination ofmucosal administration and administration to the lungs.
9. The method according to any one of claims 1 to 3 wherein the antidepressant is administered by a combination of local administration and administration to the lungs. The method according to claim 9 wherein local administration is topical administration to the penis and administration to the lungs is nasal administration.
11. The method according to any one of the preceding claims wherein the antidepressant is administered by a combination ofmucosal administration, local administration and administration to the lungs.
12. The method according to any one of the preceding claims wherein the antidepressant is administered in an amount of between 0.1 and 1000 mg per dose.
13. The method according to any one of the preceding claims wherein the antidepressant is administered in an amount of between 1 and 100 mg per dose
14. The method according to any one of the preceding claims wherein the antidepressant is administered in an amount of between 5 and 25 mg per dose -18- The method according to claim 1 wherein a single antidepressant or single combination of antidepressants is administered by two or more routes selected from the mucosal administration, administration to the lungs and local administration to at least a part of the male genitalia.
16. The method according to claim 1 wherein two or more different antidepressants or two or more different combinations of antidepressants are administered by two or more routes selected from the mucosal administration, administration to the lungs and local administration to at least a part of the male genitalia.
17. The method according to claim 16 wherein the antidepressant combination includes serotonin reuptake inhibitor (SSRIs) and a monoamine oxidase inhibitor.
18. The method according to claim 1 wherein the antidepressant is massaged into the skin of the male genitalia prior to intercourse for about one minute.
19. The method according to claim 18 wherein the antidepressant is massaged into the skin of the male genitalia about 30 to 60 minutes prior to intercourse. The method according to claim 1 wherein the antidepressant is taken.nasally within 30 minutes prior to intercourse.
21. Themethod according to claim 20 wherein the antidepressant is taken nasally just prior to intercourse -19-
22. The method according to claim 20 or 21 administered nasally by means of one or two metered doses shortly before intercourse.
23. The method according to claim 1 wherein the antidepressant is administered by way of a troche or suppository prior to intercourse.
24. A method of treating premature ejaculation in a male comprising the step of administering to the male an antidepressant, wherein the antidepressant is administered via a route selected from the group consisting of i) nasal administration, ii) administration to the lungs, iii) buccal administration, iv) administration to the penis, and v) a combination of two or more of nasal administration, administration to the lungs, buccal administration and local administration to the penis, thereby to provide a sufficient degree of anaesthesia to the penis to overcome premature ejaculation. A method of prolonging sexual intercourse involving a male, the method including the step of administering to the male prior to intercourse an amount of an antidepressant effective to delay ejaculation; and wherein the antidepressant is administered via a route selected from the group consisting of: mucosal administration, administration to the lungs, topical administration to the male genitalia, and a combination of two or more of mucosal administration, administration to the lungs or topical administration to the male genitalia.
26. A method of prolonging sexual intercourse involving a male and a female, the method including the step of administering to the male prior to intercourse an amount of an antidepressant effective to delay ejaculation without anaesthetising the female genitalia; and wherein the antidepressant is administered via a route selected from the group consisting of: mucosal administration, administration to the lungs, topical administration to the male genitalia, and a combination of two or more of mucosal administration, administration to the lungs or topical administration to the male genitalia.
27. A composition for the treatment of premature ejaculation, said composition comprising an antidepressant formulated for mucosal administration, administration to the lungs and/or local administration to at least part of the male genitalia.
28. The composition according to claim 27 wherein said antidepressant is selected from serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, norepinephrine dopamine reuptake inhibitors, serotonin antagonist and reuptake inhibitors, norepinephrine antagonist/serotonin antagonists, synthetically derived phenylpiperazine antidepressants, antagonists of central L2-a2 auto and heteroadrenoceptors, and mixtures thereof.
29. The composition according to claim 28 wherein said antidepressant is a mixture of a serotonin reuptake inhibitor and a monoamine oxidase inhibitor. The composition according to claim 29 wherein said serotonin norepinephrine reuptake inhibitor is a bicyclic, tricyclic or tetracyclic antidepressant. -21-
31. The composition according to any one of claims 27 to 30 wherein said antidepressant is selected from paroxetine, fluoxoetine, sertraline, citalopram hydrobromide, fluvoxamine, sertraline, nortriptyline hydrochloride, clomipramine hydrochloride, dothiepin hydrochloride, Imipramine hydrochloride, mianserin hydrochloride, amitriptyline hydrochloride, phenelzine sulphate, tranylcypromine sulphate, isocarboxazid, moclobemide, serotonin and/or adrenalin update inhibitors such as venlafaxine, nefazodone hydrochloride, trazodone, bupropion, mirtazapine, doxepin hydrochloride, trimipramine or mixtures thereof.
32. The composition according to claim 31 wherein said antidepressant is selected from paroxetine, fluoxoetine, sertraline or mixtures thereof.
33. The composition according to claim 32 wherein said paroxetine is formulated as a hydrochloride or mesylate.
34. The composition according to any one of claims 27 to 33 including a carrier to facilitate the administration of the antidepressant. The composition of any one of the preceding claims having a pH of around 7.4.
36. The composition according to any one of claims 27 to 35 formulated for local administration directly to the penis.
37. The composition according to any one of claims 27 to 36 for local administration to the penis in the form of a gel, lotion or a powder. -22-
38. The composition according to claim 37 wherein said powder can be hydrated to form a gel or lotion.
39. The composition according to claim 38 wherein said gel is a hydrogel or an acrylic acid polymer. The composition according to any one of claims 36 to 39 further comprising an enhancer agent for enhancing the absorption of the antidepressant agent through the skin.
41. The composition according to claim 40 wherein the enhancer agent is a cyclodextrin, water, a monohydric alcohol, a polyhydric alcohol 42 The composition according to claim 41 wherein the enhancer is ethanol, polyethylene glycol and propylene glycol or their mixtures thereof.
43. The composition according to claim 42 comprising: about 20 to about 60% water; about 80% to about 40% alcohols 1 to 10% Hydroxypropyl-3-cyclodextrin (HPBCD) and wherein antidepressant agent and the HPBCD are typically present in the composition in a molar ratio of about 1:0.8 to 1:1.4 respectively. 23
44. The composition according to claim 43 wherein said HPBCD has a degree of substitution 5 to 7. The composition according to any one of claims 27 to 44 wherein the concentration of the antidepressant is between about 1 to 10% by weight of said composition.
46. The composition according to claim 45 wherein the amount is about 3 to 6% by weight of the composition. 47 The composition according to claim 27 for mucosal administration and formulated as a nasal spray, as a troche for buccal administration or in the form of a suppository for rectal administration.
48. The composition according to claim 47 wherein said nasal spray is in the form of an aqueous or non-aqueous gel, suspension, liposomal dispersion, emulsion or microemulsion or in powdered, microsphere, coated microsphere or liposomal form.
49. The composition according to claim 48 formulated for administration to the lungs via inhalation and in the form of a dry powder, a micronized drug suspended in a liquefied propellant, or a drug dissolved, either alone or by way of a cosolvent, in a liquefied propellant. The composition according to claim 49 wherein the particle size of the dry powder is less than -24-
51. The composition according to claim 49 in the form of an aerosol and wherein said propellant is CFC (chlorofluorocarbon) or HFA (hydrofluoroalkane) propellants.
52. The composition according to claim 49 including a surface active agent selected from oleic acid, sorbitan trioleate, lecithin and their mixtures thereof.
53. A kit comprising an antidepressant formulated for nasal administration and an antidepressant formulated for local administration to at least part of the male genitalia.
54. A kit comprising an antidepressant formulated for administration to the lungs and an antidepressant formulated for local administration to at least part of the male genitalia.
55. A kit comprising an antidepressant formulated for nasal administration and an antidepressant formulated for administration to the lungs.
56. A kit comprising an antidepressant formulated for nasal administration, an antidepressant formulated for administration to the lungs and an antidepressant formulated for local administration to at least part of the male genitalia.
57. A kit according to any one of claims 29 to 32 wherein said antidepressants are selected such that they act synergistically on administration.
58. Use of an antidepressant in the manufacture of a medicament for the treatment of premature ejaculation in a male, said antidepressant being administered via a route selected from the group consisting of i) mucosal administration, ii) administration to the lungs iii) local administration to at least a part of the male genitalia and iv) a combination of two or more ofmucosal administration, administration to the lungs and local administration to at least a part of the male genitalia.
59. Use of an antidepressant in the manufacture of a medicament for treating premature ejaculation in a male comprising the step of administering to said male an antidepressant, wherein said antidepressant is administered via a route selected from the group consisting of i) nasal administration, ii) administration to the lungs, iii) buccal administration, iv) local administration to the penis, and v) a combination of two or more of nasal administration, administration to the lungs, buccal administration, and local administration to the penis, thereby to provide a sufficient degree of anaesthesia to the penis to overcome premature ejaculation. Use of an antidepressant in the manufacture of a medicament for prolonging sexual intercourse involving a male, said method including the step of administering to said male prior to intercourse an amount of an antidepressant effective to delay ejaculation; and wherein said antidepressant is administered via a route selected from the group consisting of: mucosal administration, administration to the lungs, topical administration to the male genitalia, and a combination of two or more ofmucosal administration, administration to the lungs or topical administration to the male genitalia. -26
61. Use of an antidepressant in the manufacture of a medicament for prolonging sexual intercourse involving a male and a female, said method including the step of administering to said male prior to intercourse an amount of an antidepressant effective to delay ejaculation without anaesthetising the female genitalia; and wherein said antidepressant is administered via a route selected from the group consisting of: mucosal administration, administration to the lungs, topical administration to the male genitalia, and a combination of two or more of mucosal administration, administration to the lungs or topical administration to the male genitalia.
AU2004222783A 2003-07-11 2004-07-09 Treatment of premature ejaculation Abandoned AU2004222783A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2004222783A AU2004222783A1 (en) 2003-07-11 2004-07-09 Treatment of premature ejaculation
AU2005100183A AU2005100183B4 (en) 2003-07-11 2005-03-02 Treatment of premature ejaculation
AU2010219328A AU2010219328A1 (en) 2003-07-11 2010-09-07 Treatment of premature ejaculation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003903597 2003-07-11
AU2004222783A AU2004222783A1 (en) 2003-07-11 2004-07-09 Treatment of premature ejaculation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2005100183A Division AU2005100183B4 (en) 2003-07-11 2005-03-02 Treatment of premature ejaculation
AU2010219328A Division AU2010219328A1 (en) 2003-07-11 2010-09-07 Treatment of premature ejaculation

Publications (1)

Publication Number Publication Date
AU2004222783A1 true AU2004222783A1 (en) 2005-02-03

Family

ID=34397737

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2004222783A Abandoned AU2004222783A1 (en) 2003-07-11 2004-07-09 Treatment of premature ejaculation
AU2005100183A Ceased AU2005100183B4 (en) 2003-07-11 2005-03-02 Treatment of premature ejaculation
AU2010219328A Abandoned AU2010219328A1 (en) 2003-07-11 2010-09-07 Treatment of premature ejaculation

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2005100183A Ceased AU2005100183B4 (en) 2003-07-11 2005-03-02 Treatment of premature ejaculation
AU2010219328A Abandoned AU2010219328A1 (en) 2003-07-11 2010-09-07 Treatment of premature ejaculation

Country Status (1)

Country Link
AU (3) AU2004222783A1 (en)

Also Published As

Publication number Publication date
AU2005100183A4 (en) 2005-04-07
AU2010219328A1 (en) 2010-09-30
AU2005100183B4 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
US20140221497A1 (en) Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
MXPA01012877A (en) Nasal delivery of apomorphine.
CZ20013344A3 (en) Pharmaceutical preparation suitable for treating erectile dysfunction
JP2004536024A (en) On-demand administration of tricyclic antidepressants and other non-SRI antidepressants to treat premature ejaculation
CN1471395A (en) Apomorphine derivatives and methods of use thereof
US20080003275A1 (en) Treatment of Premature Ejaculation
US20200060992A1 (en) Therapeutical methods, formulations and nutraceutical formulations
EP1237538A2 (en) An improved pharmaceutical composition for treating male erectile dysfunction
HUP0302436A2 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
WO2002024202A1 (en) Nasal delivery of apomorphine in combination with glycol derivatives
AU2005100183A4 (en) Treatment of premature ejaculation
ZA200404053B (en) Use of desoxypeganine for treating clinical depression.
WO1999025355A1 (en) Method of treating addiction to nicotine products
JP2019073493A (en) Treatment of vulvodynia
JP2002370977A (en) Topical composition
WO2008106738A1 (en) Compositions for the treatment of sexual dysfunction
JP2003089642A (en) Pharmaceutical composition for treating erectile dysfunction
WO2010044094A2 (en) A topical composition for the treatment of erectile dysfunction
HK1091418B (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
HK1093890A (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PE PATENT HOLDCO PTY LTD

Free format text: FORMER APPLICANT(S): VAISMAN, JAKOV

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted